Bicycle Therapeutics Signs 15-Year Contract with UK Nuclear Decommissioning Authority
Bicycle Therapeutics announced it has entered into a 15-year contract including an option to renew with the UK Nuclear Decommissioning Authority for access to up to 400 tons of reprocessed uranium. RepU continually regenerates providing a potentially sustainable supply of 212Pb. Bicycle intends to utilize the RepU provided by this agreement in its development of potential lifesaving therapies. In addition, Bicycle announced a collaboration with United Kingdom National Nuclear Laboratory, pursuant to which it plans to extract 228Th from the RepU obtained from NDA. The extracted 228Th will then be further processed into 224Ra and loaded into a bespoke 212Pb generator being developed exclusively for Bicycle by SpectronRx. 212Pb is a radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha Therapy. Collectively, this bespoke set of arrangements is designed to support the potential discovery, development, and commercial supply of a portfolio of Bicycle Radioconjugates containing 212Pb.
Trade with 70% Backtested Accuracy
Analyst Views on BCYC
About BCYC
About the author

Bicycle Therapeutics Signs 15-Year Contract with UK NDA for 400 Tonnes of Reprocessed Uranium
- Strategic Partnership: Bicycle Therapeutics has signed a 15-year contract with the UK Nuclear Decommissioning Authority to access up to 400 tonnes of reprocessed uranium, which is expected to provide a sustainable supply of 212Pb for its potential lifesaving therapies, significantly enhancing its competitive edge in the radiopharmaceutical sector.
- Technological Innovation: Through collaboration with the UK National Nuclear Laboratory, Bicycle plans to extract 228Th from the reprocessed uranium and further process it into 224Ra, developing a bespoke 212Pb generator that will drive the development of its radioconjugate portfolio.
- Market Potential: Bicycle's radioconjugates (BRCs) will utilize 212Pb as a potent therapeutic payload against cancer, expected to offer new treatment options for cancer patients worldwide, presenting significant market opportunities and societal impact.
- R&D Progress: Bicycle aims to present initial EphA2 human imaging data in the first half of 2026 and initiate its own clinical study, marking ongoing advancements in radiopharmaceutical development and establishing its position as a potential leader in the field.

Bicycle Therapeutics Signs 15-Year Contract with UK NDA for 400 Tonnes of Reprocessed Uranium
- Long-Term Partnership: Bicycle Therapeutics has signed a 15-year contract with the UK Nuclear Decommissioning Authority, securing access to up to 400 tonnes of reprocessed uranium, which will provide a sustainable raw material supply for its potential lifesaving therapies, significantly enhancing the company's R&D capabilities.
- Radioisotope Development: Through collaboration with the UK National Nuclear Laboratory, Bicycle plans to extract 228Th from the reprocessed uranium, further processing it into a 212Pb generator, with the potential to deliver tens of thousands of doses of 212Pb annually, advancing targeted cancer therapies.
- Customized Generator: Bicycle has partnered with SpectronRx to develop a bespoke 212Pb generator, with initial quantities of 212Pb successfully produced, which will provide strong support for the company's competitive position in the radiopharmaceutical market.
- Strategic Investment Outlook: The CEO of Bicycle stated that these collaborations demonstrate the company's potential in radiopharmaceutical R&D, with expectations to advance its BRC product line and present initial human imaging data in the first half of 2026, further solidifying its market position.






